Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18769444 | 0.95 | SLC6A3 (0.57) | SLC6A3SLC6A4LMNA | |
| Hydrochloric Acid SCHEMBL18742757 | 0.93 | SLC6A3 (0.55) | SLC6A3SLC6A4LMNA | |
| SCHEMBL3604519 | 0.91 | SLC6A3 (0.56) | SLC6A3SLC6A4LMNA | |
| Hydrochloric Acid SCHEMBL28980512 | 0.81 | SLC6A3 (0.48) | SLC6A3SLC6A4LMNA | |
| SCHEMBL613966 | 0.81 | SLC6A3 (0.48) | SLC6A3SLC6A4LMNA | |
| SCHEMBL3517809 | 0.78 | SLC6A3 (1.00) | SLC6A3SLC6A4LMNA | |
| SCHEMBL8804172 | 0.76 | SLC6A3 (0.57) | SLC6A3SLC6A4LMNA | |
| SCHEMBL558007 | 0.76 | SLC6A3 (0.97) | SLC6A3SLC6A4LMNA | |
| SCHEMBL8285885 | 0.75 | SLC6A3 (0.62) | SLC6A3SLC6A4LMNA | |
| SCHEMBL21937622 | 0.75 | SLC6A3 (0.55) | SLC6A3SLC6A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0674651-A1 | SUBSTITUTED 6-AZAANDROSTENONES | GLAXO WELLCOME INC. (US) | 1995-10-04 | — | — | EP | claimed |
| WO-1994014833-A2 | SUBSTITUTED 6-AZAANDROSTENONES | GLAXO WELLCOME INC. (US) | 1994-07-07 | — | — | WO | claimed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| EP-0674651-B1 | SUBSTITUTED 6-AZAANDROSTENONES | GLAXO WELLCOME INC (US) | 1998-10-28 | — | — | EP | disclosed |
| US-5708001-A | TESTOSTERONE-5A-REDUCTASE INHIBITORS | GLAXO WELLCOME INC. (US) | 1998-01-13 | — | — | US | disclosed |
| EP-0674651-A1 | SUBSTITUTED 6-AZAANDROSTENONES | GLAXO WELLCOME INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994014833-A2 | SUBSTITUTED 6-AZAANDROSTENONES | GLAXO WELLCOME INC. (US) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | SLC6A3 3457/4885SLC6A4 2173/4885LMNA 3934/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | SLC6A3 1318/4885SLC6A4 772/4885LMNA 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.